News: Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

750.60INR
22 Jul 2014
Price Change (% chg)

Rs6.90 (+0.93%)
Prev Close
Rs743.70
Open
Rs749.00
Day's High
Rs757.80
Day's Low
Rs745.55
Volume
779,530
Avg. Vol
2,374,440
52-wk High
Rs757.80
52-wk Low
Rs475.35

Search Stocks
Select another date:

Tue, Jul 15 2014

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

UPDATE 1-India's Ranbaxy posts loss after write-offs on US import bans

* Compares with analysts' forecast for 958.7 mln in profit

India's Ranbaxy posts March-quarter loss on write-offs

MUMBAI, May 9 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a surprise loss in the March quarter due to write-offs related to regulatory sanctions for poor manufacturing quality.

UPDATE 1-Market Chatter-Corporate finance press digest

(Adds item on Freshpet LLC, El Pollo Loco Inc, Sun Pharmaceutical Industries Ltd, Go Daddy Group)

India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S.: sources

MUMBAI - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.

Update-Moody's: Daiichi Sankyo Will Benefit from Sun Pharma's Acquisition of Ranbaxy

Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)

Deals of the day- Mergers and acquisitions

April 7 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

CORRECTED-India's Sun Pharma expects Ranbaxy business to be profitable in short term

(Corrects first and last paragraphs to say Dilip Shanghvi is managing director, not chairman of Sun Pharma)

India's Ranbaxy slumps, Sun Pharma surges on $3.2-billion acquisition

MUMBAI - Shares in India's Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after Sun Pharmaceutical Industries Ltd said it will buy the company in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker.

Select another date:
Search Stocks